Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVOGet Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Trading Down 3.3 %

Shares of ONVO stock opened at $0.36 on Friday. The firm has a fifty day simple moving average of $0.42 and a 200-day simple moving average of $0.56. The company has a market capitalization of $5.53 million, a PE ratio of -0.34 and a beta of 0.53. Organovo has a twelve month low of $0.32 and a twelve month high of $1.74.

Institutional Trading of Organovo

An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC purchased a new stake in Organovo Holdings, Inc. (NASDAQ:ONVOFree Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned about 6.46% of Organovo as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.23% of the company’s stock.

About Organovo

(Get Free Report)

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Recommended Stories

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.